University at Buffalo
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, University at Buffalo sits in the top decile of US sponsors by registered trial count (#312 of 15,742 sponsors by registered trial count).
University at Buffalo: 67 sponsored US clinical trials, none currently recruiting.
University at Buffalo sponsors 67 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 59 completed. 16 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Multiple Sclerosis, with 4 trials.
Top-decile sponsor footprint
University at Buffalo ranks in the top decile of sponsors by registered trial count (#312 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
59 of 66 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (89.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
67 total, page 1 of 2
University At Buffalo Campus Veggie Van Mobile Market
NCT06681909
Implementation of Innovative Food Prescription Programs in Older Adults
NCT06324630
Yoga as Mindful Movement: A Randomized Controlled Trial
NCT07088003
ED Recovery Course Online RCT
NCT04557566
Multi-center Database Registry to Study Thalamus Changes Using AI in MS
NCT03920995
Effectiveness and Implementation of a Research Tested Mobile Produce Market
NCT04246593
Teriflunomide Tecfidera LMCE
NCT03526224
Thyroid Disease and Chronic Periodontitis
NCT03369405
Efficacy of Eat Breathe Thrive, a Yoga-Based Program
NCT03348345
Effects of a Yoga-Based Course in Preventing Disordered Eating in Female Collegiate Athletes
NCT03347071
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
NCT03025269
Novel Airway Device to Aid Endotracheal Intubations
NCT03340207
Increasing Exercise Enjoyment and Outcome Expectations Among Women With Obesity
NCT03236077
GLP-1 Receptor Agonist Therapy and Albuminuria in Patients With Type 2 Diabetes
NCT03029351
Role of Transcranial Direct Current Stimulation in Appetite and Weight Control
NCT05609604
An Investigation Into the Effect of Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02962492
Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries
NCT02980835
Anti-inflammatory Effects of the Fiber
NCT02868788
Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes
NCT02777073
An Investigation Into The Anti-hypertensive And Potential Anti-inflammatory Actions Of Dapagliflozin
NCT02433678
Sub-Threshold Exercise Treatment for Adolescents With Sports Related Concussion
NCT02710123
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes
NCT02518945
Use of Dexamethasone in Pediatric Asthma Exacerbations
NCT02192827
Evaluate the Effect of Switching From Daily Injections of 20mg Glatiramer Acetate (GA) to 40mg GA Three Times a Week in Subjects With Relapsing-remitting Multiple Sclerosis
NCT02308670
The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects
NCT02372630
Studying the Effects of Copaxone on Retinal Health Using Optical Tomography Over 24 Months
NCT02017808
Effects of Gilenya (Fingolimod) on Thalamus Pathology and Cognitive Impairment in Patients With Relapsing Forms of Multiple Sclerosis
NCT02021162
Validation of an iPhone-based Event Recorder for Arrhythmia Detection
NCT02005172
Th Effects of Aubagio on Brain Pathology in Multiple Sclerosis Studied Over 12 Months
NCT01881191
Safety Study for Adolescents With Concussion
NCT02714192
Intensive Insulin Therapy With Tight Glycemic Control to Improve Outcomes After Endovascular Therapy for Acute Ischemic Stroke
NCT02054429
Liraglutide In Overweight Patients With Type 1 Diabetes
NCT01753362
Liraglutide in Type 1 Diabetes
NCT01722240
Liraglutide in the Treatment of Type 1 Diabetes Mellitus
NCT01722266
Natalizumab Temporary Discontinuation Study
NCT02775110
A Longitudinal Study of Effect of Copaxone in RRMS Over 24 Months
NCT01695434
Liraglutide in Adolescents With Type 1 Diabetes
NCT02516657
A Longitudinal Study of Brain Atrophy in MS Patients Over 5 Years
NCT01847287
To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
NCT01420328
Influence of a Computer Game on Youth's Choices of Activities
NCT01409629
Vancomycin-Associated Nephrotoxicity
NCT01216540
Anti-inflammatory Effects of Fiber
NCT02781350
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer
NCT01380925
Prospective Randomized Endovascular Therapy in Multiple Sclerosis
NCT05380362
Testosterone Replacement in Men With Diabetes and Obesity
NCT01127659
The Protective Effect of Friendship on Peer Rejection in Overweight and Normal Weight Youth
NCT01324661
Assessment of Lesion Activity Analysis in the Avonex- Steroid Azathioprine (ASA) Study
NCT01628315
Influence of Parents and Friends on Children and Adolescents
NCT00875576
Resveratrol in Type2 Diabetes and Obesity
NCT01158417
Effects of a Computer Game on Activity Choices
NCT00875511
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
| Phase 3 | 6 |
| Phase 4 | 10 |
How the University at Buffalo archive is shaped
67 indexed studies, none listed as recruiting (0% open); 59 completed (88%).
Phase mix: 16 late (III/IV) vs 4 early (I/II) (later-stage heavy).
Top condition: Multiple Sclerosis (4 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
University at Buffalo: archived-pipeline peers nationwide
Peers matched on 67 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
University at Buffalo sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 67 archived trials
- Prisma Health-Upstate · 67 trials · 9% recruiting
- Vanda Pharmaceuticals · 68 trials · 22% recruiting
- Alkermes · 66 trials · 9% recruiting
- Cornell University · 66 trials · 15% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this University at Buffalo page
67 registered trials is a research-attention snapshot, not an endorsement of University at Buffalo or any single study.
- None of University at Buffalo's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Multiple Sclerosis is the condition University at Buffalo studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Multiple Sclerosis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University at Buffalo pipeline card: 67 registered trials from official public datasets.Report a data error.